Add on topical 0.05% cyclosporine A to post-refractive surgery treatment can reduce inflammation dry eye disease symptoms: Study
Recent research showed that adding topical 0.05% CsA eye drops to conventional therapy greatly improved ocular surface stability after FS-LASIK. The new approach increased anti-inflammatory effects and hastened recovery; therefore, it looked promising as a new adjunct treatment for post-LASIK patients. A study on this was published in Eye and Contact Lens by Zhao Lu and co-authors.
FS-LASIK is one of the most common refractive surgeries aimed at correcting vision; however, instability on the ocular surface in the postoperative stage may reduce recovery and raise discomfort to patients. Topical antibiotics, corticosteroids, and artificial tears are conventionally applied medications for such patients. The current study evaluated whether the addition of 0.05% CsA eye drops would promote ocular healing and reduce inflammation after FS-LASIK.
Sixty-six patients (eyes) undergoing FS-LASIK were randomized into two groups. Group I (33 eyes) received conventional treatment: topical levofloxacin, fluorometholone, and artificial tears. Group II (33 eyes) received the same conventional treatment plus 0.05% CsA eye drops twice daily for three months. The key outcome measures were the Ocular Surface Disease Index, numerical rating scale, tear break-up time, Schirmer I test, corneal fluorescein staining, conjunctival lissamine green staining, corneal sensitivity, and corneal nerve morphology. The inflammatory levels of cytokines in tears were measured with the Luminex assay. Patients had to be assessed preoperatively and at 1 and 3 months postoperatively.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.